Literature DB >> 27251010

Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets.

Ryo Sato1,2, Takashi Semba1,3, Hideyuki Saya1, Yoshimi Arima1.   

Abstract

Cancer stem cells (CSCs) constitute a small subpopulation of cancer cells with stem-like properties that are able to self-renew, generate differentiated daughter cells, and give rise to heterogeneous tumor tissue. Tumor heterogeneity is a hallmark of cancer and underlies resistance to anticancer therapies and disease progression. The epithelial-mesenchymal transition (EMT) is a reversible phenomenon that is mediated by EMT-inducing transcription factors (EMT-TFs) and plays an important role in normal organ development, wound healing, and the invasiveness of cancer cells. Recent evidence showing that overexpression of several EMT-TFs is associated with stemness in cancer cells has suggested the existence of a link between EMT and CSCs. In this review, we focus on the roles of CSCs and EMT signaling in driving tumor heterogeneity. A better understanding of the dynamics of both CSCs and EMT-TFs in the generation of tumor heterogeneity may provide a basis for the development of new treatment options for cancer patients. Stem Cells 2016;34:1997-2007.
© 2016 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Entities:  

Keywords:  Cancer stem cell; Epithelial-mesenchymal transition; Therapeutic resistance; Tumor heterogeneity

Mesh:

Year:  2016        PMID: 27251010     DOI: 10.1002/stem.2406

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  55 in total

1.  Epithelial-mesenchymal transition is predetermined by the epigenetic state of the skin tumor cell of origin.

Authors:  Takashi Semba; Yoshimi Arima
Journal:  Stem Cell Investig       Date:  2017-05-09

2.  O-Linked N-Acetylglucosamine (O-GlcNAc) Expression Levels Epigenetically Regulate Colon Cancer Tumorigenesis by Affecting the Cancer Stem Cell Compartment via Modulating Expression of Transcriptional Factor MYBL1.

Authors:  Huabei Guo; Bing Zhang; Alison V Nairn; Tamas Nagy; Kelley W Moremen; Phillip Buckhaults; Michael Pierce
Journal:  J Biol Chem       Date:  2017-01-17       Impact factor: 5.157

Review 3.  Claudin proteins, outside-in signaling, and carcinogenesis.

Authors:  Amar B Singh; Srijayaprakash B Uppada; Punita Dhawan
Journal:  Pflugers Arch       Date:  2016-12-17       Impact factor: 3.657

4.  Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas.

Authors:  Monia Orciani; Miriam Caffarini; Giulia Sorgentoni; Riccardo Antonio Ricciuti; Giorgio Arnaldi; Roberto Di Primio
Journal:  Pituitary       Date:  2017-04       Impact factor: 4.107

Review 5.  Pituitary adenomas, stem cells, and cancer stem cells: what's new?

Authors:  M Caffarini; M Orciani; L Trementino; R Di Primio; G Arnaldi
Journal:  J Endocrinol Invest       Date:  2017-12-08       Impact factor: 4.256

6.  ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance.

Authors:  Dimitrios Tsoumas; Sofia Nikou; Efstathia Giannopoulou; Spyridon Champeris Tsaniras; Chaido Sirinian; Ioannis Maroulis; Stavros Taraviras; Vassiliki Zolota; Haralabos P Kalofonos; Vasiliki Bravou
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

7.  Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.

Authors:  Byoung-Ae Kim; Hyeon-Gun Jee; Jin Wook Yi; Su-Jin Kim; Young Jun Chai; June Young Choi; Kyu Eun Lee
Journal:  Cancer Genomics Proteomics       Date:  2017-01-02       Impact factor: 4.069

8.  General anesthesia versus monitored anesthesia care during endovascular therapy for vertebrobasilar stroke.

Authors:  Guangjun Hu; Zhen Shi; Bixi Li; Weidong Shao; Bo Xu
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 9.  Role of CD44 isoforms in epithelial-mesenchymal plasticity and metastasis.

Authors:  Mark Primeaux; Saiprasad Gowrikumar; Punita Dhawan
Journal:  Clin Exp Metastasis       Date:  2022-01-12       Impact factor: 5.150

10.  Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.

Authors:  Tsatsral Iderzorig; Joseph Kellen; Chike Osude; Sanjana Singh; James A Woodman; Christian Garcia; Neelu Puri
Journal:  Biochem Biophys Res Commun       Date:  2018-01-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.